HanmiPharm announced on the 17th that it presented the Phase 1 clinical trial results for both candidates as posters at the European Society for Medical Oncology (ESMO) Congress 2026, held in Madrid, Spain, from the 23rd to the 27th of last month.
HM97662 is a next-generation dual-inhibitor targeted anticancer drug candidate that simultaneously inhibits the EZH1 and EZH2 proteins, which are involved in gene expression regulation. These two proteins are key components of the “Polycomb Repressor Complex 2” (PRC2), which plays a role in the growth and survival of cancer cells. Given the possibility that EZH1 could compensate for the function of EZH2 when only EZH2 is inhibited, the drug is being developed to block both targets simultaneously.
This announcement presents the results of a randomized, dose-finding phase 1 clinical trial evaluating the safety, pharmacokinetics, and antitumor activity in the 200 mg and 300 mg dose groups. According to the company, the safety profile was generally manageable in both dose groups.
Antitumor activity was observed in patients with ovarian clear cell carcinoma harboring ARID1A mutations and in patients with SMARCB1-deficient chordoma. The company explained that, following the preliminary results from the dose-escalation phase presented at last year’s ESMO, antitumor activity was also confirmed in patients with mesothelioma and SMARCA4-deficient uterine sarcoma.
Based on these results, HanmiPharm plans to pursue further development targeting patients with solid tumors that exhibit abnormalities in chromatin regulatory systems, such as SWI/SNF. The company intends to further evaluate safety and antitumor activity during the upcoming dose-expansion phase.
The company also released the first clinical data on the bispecific antibody candidate BH3120. BH3120 was designed using HanmiPharm’s “Pentamabody” bispecific antibody platform to simultaneously target PD-L1 and 4-1BB on the surface of immune cells. The goal is to activate 4-1BB signaling in an environment where PD-L1 is expressed, thereby enhancing the immune response at the tumor site.
This study evaluated the safety and other parameters of BH3120 monotherapy in 45 patients with advanced solid tumors using a dose-escalation approach. No dose-limiting toxicities (DLTs) were observed in any of the dose groups tested, and the maximum tolerated dose (MTD) was not reached.
In particular, no Grade 3 or higher toxicity was observed regarding hepatotoxicity, including elevated liver enzyme levels. Given that the development of some existing 4-1BB-targeting antibody candidates has been hampered by issues such as hepatotoxicity, the company attached significant importance to these safety results. It also explained that initial antitumor activity was observed across various patient populations with solid tumors.
However, as both candidates are in the early clinical stages, follow-up studies are necessary to assess their therapeutic efficacy and safety. The data released this time did not include specific metrics for evaluating antitumor activity, such as objective response rate or duration of response.
Lee Moon-hee, Head of the Clinical Team (Senior Managing Director) at HanmiPharm, stated, “We have confirmed the differentiated competitiveness of HM97662 and BH3120 based on their Phase 1 clinical data,” adding, “We plan to develop them into therapies that can improve clinical outcomes for patients in areas with high unmet medical needs.”